DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Peregrine Capital Management LLC

Peregrine Capital Management LLC lowered its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 4.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 588,748 shares of the medical device company's stock after selling 29,135 shares during the quarter. DexCom accounts for about 1.4% of Peregrine Capital Management LLC's investment portfolio, making the stock its 15th largest position. Peregrine Capital Management LLC owned approximately 0.15% of DexCom worth $45,787,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Geode Capital Management LLC increased its position in DexCom by 2.2% in the third quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company's stock worth $664,056,000 after purchasing an additional 214,136 shares during the last quarter. Jennison Associates LLC grew its holdings in shares of DexCom by 10.3% in the fourth quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company's stock worth $594,455,000 after purchasing an additional 710,858 shares during the last quarter. Groupama Asset Managment grew its holdings in shares of DexCom by 1.1% in the third quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company's stock worth $1,912,000 after purchasing an additional 31,358 shares during the last quarter. Westfield Capital Management Co. LP grew its holdings in shares of DexCom by 44.6% in the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company's stock worth $190,532,000 after purchasing an additional 876,739 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of DexCom by 11.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,734,155 shares of the medical device company's stock worth $183,298,000 after purchasing an additional 288,381 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on DXCM shares. Sanford C. Bernstein upped their price objective on shares of DexCom from $82.00 to $86.00 and gave the stock an "outperform" rating in a research note on Friday, October 25th. Baird R W upgraded shares of DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Robert W. Baird raised shares of DexCom from a "neutral" rating to an "outperform" rating and raised their price objective for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Raymond James dropped their price objective on shares of DexCom from $115.00 to $99.00 and set a "strong-buy" rating on the stock in a research note on Friday, October 25th. Finally, StockNews.com lowered DexCom from a "buy" rating to a "hold" rating in a research report on Saturday, November 2nd. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $99.06.

DexCom Trading Down 0.6 %

Shares of NASDAQ:DXCM traded down $0.56 during midday trading on Friday, reaching $88.78. 3,729,437 shares of the company's stock were exchanged, compared to its average volume of 3,632,823. The firm's 50 day simple moving average is $83.26 and its two-hundred day simple moving average is $75.94. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The stock has a market cap of $34.69 billion, a price-to-earnings ratio of 62.08, a P/E/G ratio of 2.31 and a beta of 1.14. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, sell-side analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Transactions at DexCom

In related news, CEO Kevin R. Sayer sold 33,359 shares of the business's stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the sale, the chief executive officer now owns 319,037 shares in the company, valued at $27,727,505.67. The trade was a 9.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of the business's stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the sale, the chief operating officer now owns 268,644 shares of the company's stock, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 38,083 shares of company stock valued at $3,309,794. 0.30% of the stock is currently owned by corporate insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.